Bristol-Myers Squibb and Eli Lilly and Company are peers in the branded pharmaceuticals segment.
1 report, 1 independent
Updated Aug 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and Eli Lilly and Company are peers in the branded pharmaceuticals segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.